SciRhom GmbH is a German biotechnology company focused on the research and development of novel therapeutics for immunology and inflammation (I&I). Their lead product is an iRhom2-targeting antibody, which offers a first-in-class opportunity for multi-pathway inhibition while promoting immune and tissue homeostasis. SciRhom aspires to provide a new treatment paradigm with “pipeline in a drug” potential to address a range of I&I diseases.
